Background {#Sec1}
==========

*Toxoplasma gondii* is a worldwide protozoan parasite that can infect virtually all warm-blooded animals, including humans. It is prevalent in most areas of the world and up to one-third of the human population is chronically infected, with an endemicity from around 10% to 70% and the prevalence is high in warmer and humid areas \[[@CR1],[@CR2]\]. Food-borne transmission of *T. gondii* is considered to be the most important route for human infection \[[@CR3],[@CR4]\], which occurs through the ingestion of raw or inadequately cooked meat containing tissue cysts, or of food or water contaminated by oocysts shed by felids. Moreover, infection acquired during pregnancy can be transmitted to the foetus, sometimes leading to serious consequences \[[@CR5]\]. *T. gondii* infection is currently incurable because the parasite can change from the rapidly replicating tachyzoite stage to the dormant bradyzoite stage, and the latter is impervious to host immunity and also to drugs. Toxoplasmosis is fatal in the immunocompromised individuals such as cancer patients with chemotherapy, HIV/AIDS patients and organ transplant recipients \[[@CR6]-[@CR8]\]. Although the infection is usually believed to be harmless and have a benign course in immunocompetent persons, it could be indirectly responsible for deaths due to its effects on the traffic and workplace accidents, and also suicides. Moreover, latent toxoplasmosis is probably one of the most important risk factors for schizophrenia \[[@CR9]\]. China is the first-most populous nation in the world (National Bureau of Statistics 2010) and a high rate of neoplasmas. Clinical toxoplasmosis in malignant patients in China is of great public health concern, since it can lead to the active parasitemia and life-threatening disease due to the rupture of pre-existent cysts, contributing to worsening of the clinical condition \[[@CR10]\]. Therefore, it becomes essential to investigate the prevalence and genetic structure of *T. gondii* in cancer patients of China.

The frequency of seropositivity of *T. gondii* varies in different countries or even in different areas of a given country. Prevalence below 30% was observed in USA, Northern Europe, and South East Asia \[[@CR11],[@CR12]\], while above 60% in the regions of tropical African and Latin America \[[@CR13],[@CR14]\]. Moreover, *T. gondii* infection ranges from 8.8% to 37.3% in women of fertile age in the Indian subcontinent \[[@CR15]\], and from 5.1% to 16.4% in populations of Kyrgyzstan, respectively \[[@CR16]\]. Walle *et al.* \[[@CR7]\] from Ethiopia reported the positive rates of 87.4% and 10.7% of anti-*Toxoplasma* IgG and IgM, respectively. Previous investigation in Brazil indicated that toxoplasmic encephalitis might reach up to 40% in patients with AIDS, among them 10-30% died \[[@CR17]\]. However, little is known in the scientific community about the epidemiology of *T. gondii* and the parasite genotypes in human populations and, particularly, in cancer patients of China.

The genetic diversity of *T. gondii* varies in different geographical regions and hosts. In North America and Europe, *T. gondii* is highly clonal and consists of three distinct lineages (types I, II and III). Type I strains are highly virulent to mice. The type II and III lineages are widespread throughout all continents and dominate in North America, Europe and Africa, meanwhile, type II strains are the most prevalent cause of human toxoplasmosis in both congenital infection and AIDS patients in North America and Europe \[[@CR18]-[@CR20]\]. In contrast, genetic characterization of isolates from human patients and animals in South America are genetically and biologically diverse \[[@CR21]\], and severe toxoplasmosis in immunocompetent human patients is often associated with atypical genotypes \[[@CR22]\]. We have previously identified limited genotypes of isolates from stray cats, pigs, sheep and chickens in China, and genotype ToxoDB\#9 (termed as Chinese 1) is widespread and is likely the major *T. gondii* lineage circulating in animals and humans in China \[[@CR23],[@CR24]\]. So far, neither detailed information on seroepidemiology of *Toxoplasma* in immunocompromised patients nor precise approaches concerning the genetic features of *T. gondii* isolates from humans have been uncovered in China. Genotyping studies of *T. gondii* in cancer patients may help reevaluate the population genetic structure, population biology and pathogenesis of this important zoonotic pathogen in China.

Herewith we examined the seroprevalence of anti-*T. gondii* antibodies, as well as the population structure of this parasite in cancer patients, and hope to provide baseline data for the implementation of effective strategies for the control and prevention of *T. gondii* infection in China.

Methods {#Sec2}
=======

Ethical aspects {#Sec3}
---------------

This study was approved by the Institutional Review Board (IRB) of the Institute of Biomedicine at Anhui Medical University (Approval No: 2012012). Participation in the study was voluntary without incentives. Both studies were carried out in accordance with good clinical practices; the purpose and procedures of the study were explained to all participants, and a written informed consent was obtained from each participating patient.

Participants and serum sample preparation {#Sec4}
-----------------------------------------

A total of 1014 inpatients and outpatients were enrolled in the study from 6 representative tertiary-care hospitals (The First Hospital of Anhui University of Chinese Medicine (HAUCM), Anhui Provincial Hospital (APH), the First Hospital of Anhui Medical University (HAMU), Xinan Hospital (XAH), the First Hospital of Hefei (FHH) and the First Hospital of Bengbu Medical College (HBMC)) in Anhui province, Eastern China, from May 2012 to August 2013. One sample from each patient was collected and the information such as gender and age were also obtained and matched. Approximately 5 ml of venous blood samples were drawn from each patient with informed consent. All the blood samples were labeled individually and cooled with ice packs to maintain the temperature at 4°C during transport to the laboratory. Blood samples were centrifuged and sera were recovered and transferred to 1.5 ml centrifuge tubes. The serum samples were stored at −80°C until tested for *T. gondii* antibodies.

Immunological test for *T. gondii* antibodies {#Sec5}
---------------------------------------------

All serum samples were analyzed by qualitative and quantitative methods for anti-*Toxoplasma* IgG and IgM antibodies by enzyme-linked immunosorbent assay (ELISA) kits commercially available (Haitai Biological Pharmaceuticals Co., Ltd, Zhuhai, China), following the manufacturer's instructions. Positive, negative, critical and blank controls supplied with the kit were included in each testing plate. In brief, sera diluted 1:100 were incubated in a *T. gondii* antigen-coated 96-well plate at 37°C for 30 min, and the plate was washed five times, then a drop of diluted HRP-labelled conjugate was added to each well. After a final washing, "A" and "B" solutions were added that are available in the kit and incubated at 37°C for 15 min. The optical density (OD) values of the test sera were corrected according to blank controls, and OD values were read using an automated microplate reader (Bio-Tek, Vermont, USA). The threshold value was determined by the mean of 3 critical controls in each test. A result equal to or greater than threshold values was considered positive.

DNA extraction and *Toxoplasma gra6* amplification {#Sec6}
--------------------------------------------------

Genomic DNA was extracted from the whole blood samples using the QIAamp Mini DNA kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The DNA samples were tested by nested PCR of the GRA6 gene. Briefly, 1.5 μl of DNA template was add to a final volume of 25 μl PCR mixture consisting of 12.5 μl PCR *Premix Taq* (TaKaRa, Dalian, China), and 1.5 μl of each of the outer primers. The amplification steps included a first cycle of denaturation at 94°C for 5 min, 35 cycles of denaturation at 94°C for 30 s, annealing at 55°C for 60 s, and extension at 72°C for 90 s, and a final extension step at 72°C for 10 min. The resulting products were diluted with equal an volume of nuclease-free water and then used as template for the nested PCR with inner primers in a total volume of 25 μl under the similar program. Each PCR set included a positive control of DNA extracted from *T. gondii* RH strain and a negative control of nuclease-free water. The PCR-generated products and molecular weight markers were subjected to electrophoresis on a 1.5% agarose gel, stained with ethidium bromide, and visualized under UV transilluminator (Hema, Zhuhai, China).

Genetic characterization of *T. gondii* in positive DNA samples {#Sec7}
---------------------------------------------------------------

DNA samples that were positive for *gra6* were subsequently genotyped by multi-locus PCR-RFLP using the genetic loci *sag1, sag2, sag3, btub, gra6, c22-8, c29-2, l358, pk1 and apico* \[[@CR25]\]. Briefly, pre-amplification was carried out using a set of mixed outer primers in a single reaction. Then, multiplex PCR-amplified products were diluted 1:1 with deionized water, and then used for nested PCR amplifications with inner primers for each locus, respectively. Eight genotype references of *T. gondii* strains were set up as positive controls including GT1, PTG, CTG, MAS, TgCatBr5, TgCatBr64, TgCgCa1 and TgRsCr1. For each locus, the PCR mixture consisted of 12.5 μl PCR *Premix Taq* (TaKaRa, Dalian, China), 1 μl 10 μm forward and reverse primers, and 1.5 μl PCR-generated products in a 25 μl reaction volume. All reaction mixtures were made up to 25 μl with deionized water. The nested PCR was carried out with an annealing temperature at 60°C for 60s for all the loci. The products were digested using restriction endonucleases (Fermentas, Vilnius, Lithuania) specific for each genetic marker according to the manufacturer's instructions. The restriction fragments were visualized by electrophoresis using a 2.5%-3% agarose gel stained with ethidium bromide and photographed using a gel documentation system (Hema, Zhuhai, China).

Data analysis {#Sec8}
-------------

Pearson Chi-Square and Fisher's exact tests were used to investigate associations among qualitative categorical variables using SPSS (SPSS Inc., Chicago, Illinois). All tests were 2-sided, and the level of significant difference was defined as *P* \< 0.05.

Results {#Sec9}
=======

Frequency of anti-*Toxoplasma* IgG and IgM antibodies {#Sec10}
-----------------------------------------------------

Data on 1014 cancer patients in age range of 27 to 91 years from six tertiary-care hospitals of Anhui province are presented in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. The mean age of the participants was 57.44 ± 12.80 years old. Males constituted 61.6% and females accounted for 38.4%. Anti *T. gondii* antibodies were detectable in sera of 85 out of 1014 cases, with an overall seroprevalence of 8.38%. Among them, 61 (6.02%) patients were seropositive for only IgG, 16 (1.58%) for only IgM, and 8 (0.79%) for both IgG and IgM, with a distribution of 5.8% (6/103) in HAUCM, 11.0% (33/299) in APH, 6.6% (4/61) in HAMU, 6.0% (5/83) in XAH, 8.9% (8/90) in FHH, and 7.7% (29/378) in HBMC, respectively. No significant difference of positive rates were found in hospitals (*χ*^2^ = 4.764, *P* = 0.445), or in age groups (*χ*^2^ = 1.172, *P* = 0.947), or in gender (*χ*^2^ = 0.707, *P* = 0.400) (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).Table 1**Age-associated seroprevalence of** ***T. gondii*** **infection in cancer patients of 6 representative hospitals** ^**\***^**Age groupHAUCMAPHHAMUXAHFHHHBMCNo. of positive/examinedSeroprevalence (%)**0-39428287235/726.940-4919731227178218/2307.850-5921681512219419/2318.260-69357816302910325/2918.670-792043133156514/1598.8≥8049331114/3112.9Total10329961839037885/10148.38^\*^ *χ* ^2^ = 1.172, p = 0.947.Table 2**Prevalence of antibodies to** ***T. gondii*** **in cancer patients by gender in Eastern China** ^**\***^**GenderNo. examinedNo. positivePrevalence (%)**Male625568.96Female389297.45Total1014858.38^\*^ *χ* ^2^ = 0.707, p = 0.400.Table 3**The rates of positivity of** ***T. gondii*** **IgG and IgM antibodies in different cancer patients** ^**\***^**Types of neoplasmsNumber of patientsPositive IgG (%)Positive IgM (%)**Lung cancer1027 (6.86)3 (2.94)Gastric carcinoma1106 (5.45)2 (1.82)Rectal carcinoma1198 (6.72)2 (1.68)Intracranial tumor131 (7.69)1 (7.69)Lymphoma211 (4.76)1 (4.76)Breast carcinoma561 (1.79)2 (3.57)Hepatocellular carcinoma22024 (10.91)8 (3.64)Cervical cancer809 (11.25)2 (2.50)Carcinoma of pancreas231 (4.35)0Esophageal carcinoma1206 (5.00)2 (1.67)Nasopharyngeal carcinoma693 (4.35)1 (1.45)Prostatic carcinoma131 (7.69)0Osteosarcoma121 (8.33)0^\*^ *χ* ^2^ = 16.675, p = 0.781.

The frequencies of IgG antibodies against *T. gondii* are presented in Table [3](#Tab3){ref-type="table"}, and no statistically significant difference was seen among the cancers (*χ*^2^ = 16.675, *P* = 0.781). Additionally, the positive rate of Toxo-IgM antibodies was the highest in intracranial tumors (7.69%), followed by lymphoma (4.76%), and the lowest in nasopharyngeal carcinoma (1.45%).

Multilocus PCR-RFLP genotyping of *T. gondii* isolates {#Sec11}
------------------------------------------------------

Of the 1014 DNA samples investigated, 36 (3.55%) were positive for *T. gondii gra6* by PCR, including 3 from lung cancer, 3 from gastric carcinoma, 3 from rectal carcinoma, 1 from lymphoma, 18 from hepatocellular carcinoma, 5 from cervical cancer, 1 from oesophageal carcinoma, 1 from nasopharyngeal carcinoma, and 1 from osteosarcoma, distributed in 24 (2.37%) IgG-positive and 12 (1.18%) IgG-negative patients.

Nine of the 36 *gra6* positive samples showed complete genotyping results, among them 7 from hepatocellular carcinoma and 2 from cervical cancer. Only one pattern of type Chinese 1 (ToxoDB\#9) was identified in the 9 samples. The electrophoresis exhibited type II pattern at *sag2*, *gra6*, *l358*, *pk1* and *c22-8*, but type III pattern at *c29-2*, *sag3*, and *btub* loci and type I pattern at the *apico* locus. The results of genotyping of *Toxoplasma* genomic DNA from humans and 8 reference strains were illustrated in Table [4](#Tab4){ref-type="table"} and Figure [1](#Fig1){ref-type="fig"}.Table 4***T. gondii*** **genotypes identified in blood of PCR positive cancer patientsIsolate IDHostSAG1SAG2SAG3BTUBGRA6c22-8c29-2L358PK1ApicoGenotype**GT1GoatIIIIIIIIIIReference, Type I, ToxoDB\#10PTGSheepII/IIIIIIIIIIIIIIIIIIIIIReference, Type II, ToxoDB\#1CTGCatII/IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIReference, Type III, ToxoDB\#2TgCgCa1CougarΙIIIIIIIIIIIμ-1^a^Ιμ-2^a^ΙReference, ToxoDB\#66MASHumanμ-1^a^IIIIIIIIIIIμ-1^a^ΙΙIIIΙReference, ToxoDB\#17TgCatBr5CatΙIIIIIIIIIIIIΙΙΙμ-1^a^ΙReference, ToxoDB\#19TgCatBr64CatΙμ-1^a^IIIIIIIIIμ-1^a^ΙIIIIIIΙReference, ToxoDB\#111TgRsCr1Toucanμ-1^a^IIIIIΙIIIμ-2^a^ΙΙIIIΙReference, ToxoDB\#52TgHuCn1, 2, 3, 4, 5, 6, 7, 8, 9Humanμ-1^a^IIIIIIIIIIIIIIIIIIIΙChinese 1, ToxoDB\#9^a^μ-1 and μ-2 represent unique RFLP genotypes, respectively.Figure 1**Representative gel image of RFLP genotyping (markers SAG1, BTUB, GRA6 and L358).** Sample IDs are at the top of the gel images, genotype results are at the bottom. GT1, PTG, CTG, Ca1 (TgCgCa1), MAS, Br5 (TgCatBr5), Br64 (TgCatBr64) and Cr1 (TgRsCr1) are reference strains. Cn1: TgHuCn1; Cn2: TgHuCn2; Cn3: TgHuCn3; Cn4: TgHuCn4; Cn5: TgHuCn5; Cn6: TgHuCn6; Cn7: TgHuCn7; Cn8: TgHuCn8; Cn9: TgHuCn9. MK: molecular markers.

Discussion {#Sec12}
==========

The human seroprevalence of *Toxoplasma* infection is high across the world, with obvious geographical variation \[[@CR26]\]. The majority of studies emerging from Latin American countries show significantly high rates of seropositivity, most of which had a prevalence above 60% \[[@CR14]\]. Frequent infections are noted in Brazil from a study in pregnant women showing a prevalence of 65.1%-68.9% \[[@CR27]\]. However, human toxoplasmosis in the United States is significantly decreased, according to the two most recent NHANES (National Health and Nutrition Examination Survey) studies, ranging from 22.5% to 12.4% \[[@CR28],[@CR29]\]. Additionally, Rai *et al.* \[[@CR30]\] reported a higher seroprevalence of *T. gondii* infection (68.7%) in Nepalese cancer patients than in those with ocular or other diseases. Similarly, high frequency of *T. gondii* infection has been detected among immunocompromised patients especially in those suffering from malignancy in Egypt and Korea \[[@CR31],[@CR32]\]. In the present study, 8.38% (85/1014) of the 1014 cancer patients were seropositive for *T. gondii* tested by ELISA, which is relatively low compared with reports from other countries \[[@CR33]\], and similar to the investigation in pregnant women of China, within the range of 0-10% \[[@CR8]\]. The seroprevalence in humans varies in regions possibly due to the geographical factors, eating habits, pet-keeping and management, as well as differences in livestock farming practices. *T. gondii* prevalence in China was reported to be 5.2% during 1988--1992 but increased to 7.9% during 2001--2004 in two separate nationwide surveys \[[@CR34]\], suggesting that toxoplasmosis may constitute a serious health problem in China.

The present survey did not show any significant difference in infection rates among malignancies, which differs to that reported in the previous investigation in China \[[@CR6]\]. The high seroprevalence in cancer patients indicates a considerable risk due to the fact that the underlying latent *Toxoplasma* infection may be activated following long term chemotherapy leading to the compromised immunity of the patients. Obviously, a comparative study is needed to demonstrate the association of *Toxoplasma* infection with pathological sources of tumors and duration of chemotherapy.

In the present study, a total of 85 patients were found to be positive for antibodies against *T. gondii* (8.38%), which corresponds to 7.9% prevalence previously surveyed in the general Chinese population \[[@CR35]\]. These results revealed that the frequency of *Toxoplasma* infection in a general hospital-based study was similar to that in a community-based study. We noted that *Toxoplasma* infection in malignant patients does not seem to increase progressively with age, which is similar to that shown with a previous study \[[@CR33]\] but is in disagreement with the report from the United States \[[@CR28]\]. The difference in target population surveyed may account for the varied results.

Genotyping of *Toxoplasma* isolates in humans is relatively rare due to the transient nature of parasitaemia. In toxoplasmosis, the initial dissemination of tachyzoites is usually limited to less than 20 day's duration but this may vary according to the genotype of infected parasite and the host immune response \[[@CR2]\]. The ability to detect *T. gondii* genomic DNA in clinical samples made it possible to directly type the infecting isolate obviating the need to harvest the parasite \[[@CR36]\]. A nested PCR with its double amplification steps was used to improve the diagnostic yield and to allow for subsequent assessment of *T. gondii* genotypes. However, a low positive rate was found among the patients with no correlation to their serological profile. In agreement with the present results, Messaritakis *et al.* \[[@CR37]\] tried to amplify *gra6* from clinical samples of 290 acutely infected patients and reported positive finding in only 3.12%. Since the primary objective of the present study was genotyping, GRA6 gene was selected in view of its higher polymorphism than other described markers. Understanding *T. gondii* population structure is of great interest, as it may provide us with essential information regarding the transmission and evolution of this widespread zoonotic parasite, and its pathogenesis as well. Based on 10 PCR-RFLP markers, the genetic variability of *T. gondii* isolates from China has been revealed gradually. A total of 10 genotypes were identified, indicating limited diversity of the parasite in China, which is in sharp contrast to South America where a variety of parasite lineages are transmitted in the environment \[[@CR22]\].

It is reported that strain genotype has been associated with clinical severity of human toxoplasmosis \[[@CR38]\]. Type II strains have been shown to be most prevalent in congenital infection and AIDS patients in North America and Europe \[[@CR20],[@CR39]\]. In our study, only one pattern of genotype Chinese 1 (ToxoDB\#9) was identified, which has been found to be widely and predominantly distributed in animal hosts such as cats, pigs, and voles in a frequency of 73.9% in China \[[@CR23],[@CR40]\]. Our results showed that *Toxopasma* DNAs of all 9 samples share the genetic pattern of type Chinese 1, which strongly suggests the pathogenic origin of human infection from animal hosts. Type Chinese1 has also been identified from Sri Lanka, Colombia, Brazil and the United States, suggesting that it might be widespread from Asia to North and South America \[[@CR24]\]. Obviously, more studies should be carried out for deep insight into the population genetic structure of *T. gondii* isolates and the clinical manifestations of patients and for providing useful information for control and prevention of human toxoplasmosis. To our knowledge, this is the first report of genetic typing of *T. gondii* from cancer patients in China.

Conclusion {#Sec13}
==========

The 8.38% seropositive rate of *Toxoplasma* infection in Anhui province coincides with the overall prevalence in China, which is relatively low compared with that in other parts of the world. The genetic feature of *Toxoplasma* isolates found in cancer patients corroborates the findings of previous studies that *T. gondii* has a limited diversity in China. Studies on a larger number of samples from different nationalities are imperative for better understanding of the parasite genetic structure and transmission of *T. gondii* in China.
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